Trial Outcomes & Findings for Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (NCT NCT01198067)
NCT ID: NCT01198067
Last Updated: 2025-09-04
Results Overview
Maximum Tolerated Dose
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
15 participants
Primary outcome timeframe
Participants Experiencing Study Medication Maximum Tolerated Dose through Study Completion (Avg. 1 Year)
Results posted on
2025-09-04
Participant Flow
Patient Eligibility:Waldenstrom relapsed,\>/18 - years old,ECOG \<\~2,Labs NCS,no prior cancers,females not preganant,\~1\> line(s) prior therapy, no therapy in 4 weeks. Excluded:pregnant, breast-feeding, serious diagnosis,chemotherapy reaction,prior pomalidomide,HIV/ Hepatitis A-C +,concurrent chemotherapy,grade\~\>2 neuropathy,andANC count \<\~1000K/ul.
Six patients were screen failures; did not meet inclusion criteria. Original study design included Arms with assignment to increasing dose escalation including 3 and 4mg Pomolidomide Arms/Cohorts; however, safety concerns early on regarding Dose Limiting Toxicities for 2mg Cohort compelled omitting the 3 and 4mg Arms/Cohorts.
Participant milestones
| Measure |
Cohort 2
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Overall Study
STARTED
|
3
|
6
|
|
Overall Study
COMPLETED
|
3
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Baseline characteristics by cohort
| Measure |
Cohort 2
n=3 Participants
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 Participants
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Total
n=9 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
|
Age, Continuous
|
67 years
STANDARD_DEVIATION 10 • n=5 Participants
|
66 years
STANDARD_DEVIATION 11 • n=7 Participants
|
66 years
STANDARD_DEVIATION 11 • n=5 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
9 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
3 participants
n=5 Participants
|
6 participants
n=7 Participants
|
9 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Participants Experiencing Study Medication Maximum Tolerated Dose through Study Completion (Avg. 1 Year)Maximum Tolerated Dose
Outcome measures
| Measure |
Cohort 2
n=3 Participants
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 Participants
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Number of Patients Experiencing MTD
|
1 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: Study Completion (Avg. 1 Year)Length of Treatment
Outcome measures
| Measure |
Cohort 2
n=3 Participants
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 Participants
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Cycles Completed
|
2 Number of Cycles
Interval 1.0 to 2.0
|
7 Number of Cycles
Interval 4.0 to 12.0
|
SECONDARY outcome
Timeframe: Through Study Completion (Avg. 1 Year)Average Paraprotein1 gm/dL Change Cycle 1 thru Study
Outcome measures
| Measure |
Cohort 2
n=3 Participants
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 Participants
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Changes in Waldestrom Biomarkers
|
0.3 Paraprotein #1 gm/dL
Standard Deviation .1
|
1.4 Paraprotein #1 gm/dL
Standard Deviation .7
|
SECONDARY outcome
Timeframe: Through Study Completion (Avg. 1 Year)Average Reduction in IgM Protein mg/dL from Cycle 1 thru Study
Outcome measures
| Measure |
Cohort 2
n=3 Participants
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 Participants
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Changes in Waldestrom Biomarkers
|
493 IgM Protein mg/dL
Standard Deviation 955
|
1252 IgM Protein mg/dL
Standard Deviation 2011
|
Adverse Events
Cohort 2
Serious events: 3 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 3
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cohort 2
n=3 participants at risk
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 participants at risk
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Nervous system disorders
Syncope
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Infection (Knee)
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Caudia Equina Syndrome
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
Other adverse events
| Measure |
Cohort 2
n=3 participants at risk
2mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
Cohort 3
n=6 participants at risk
1mg Pomolidomide per day per Cycle (Cycle = 28 days)
|
|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Allergy/Immunology (Other) - Allergic Sinusitis
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Allergy/Immunology (Other) - Lidocaine
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Allergy/Immunology (Other) - Respiratory
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Anxiety
|
66.7%
2/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Blood glucose increased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Vascular disorders
Bruising
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Bruising - Injury / Laceration
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Conjunctival disorder
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Constipation
|
66.7%
2/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Constitutional Symptoms (Other) - Pelvic Cystic Mass
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Creatinine increased
|
33.3%
1/3 • Number of events 4 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Depression
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other)
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other) - Injury / Laceration
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 10 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other) - non-malignant growths
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other) - Rash NOS
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other) - Rash: Erithematous
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other) - SCC
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Dermatology/Skin (Other)- non-malignant skin cancer
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Diarrhea
|
33.3%
1/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
66.7%
4/6 • Number of events 5 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Dizziness
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Dry eye syndrome
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Edema limbs
|
66.7%
2/3 • Number of events 7 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
66.7%
4/6 • Number of events 5 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Eye pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Eyelid function disorder - Eyelid edema
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Facial pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Fatigue
|
100.0%
3/3 • Number of events 8 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
100.0%
6/6 • Number of events 14 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Fever
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 5 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Gastrointestinal (Other) - Colorectal polyps
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Gastrointestinal (Other) - GERD
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Gingival infection
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Gingival pain
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Headache
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Hemoglobin decreased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
83.3%
5/6 • Number of events 8 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Hypertension
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Infections and infestations
Infection - COVID +
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Infections and infestations
Infection - Human Rhinovirus
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Insomnia
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Joint disorder
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Joint infection
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal inflamation
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngitis
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Leukopenia
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Blood and lymphatic system disorders
Lymphatics (Other) - Left axillary nodule
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Anemia
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Hypercapnia
|
100.0%
3/3 • Number of events 3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Hyperglycemia
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Hypomagnesemia
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Hypophosphatemia
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Lymphocyte Abs increased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Metabolic/Laboratory (Other) - Vitamin D defficiency
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Mucositis oral
|
66.7%
2/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal (Other) - Cramps
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal (Other) - Injury
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal (Other) - muscle aches
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal (Other) - Pulled muscle
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
33.3%
1/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
50.0%
3/6 • Number of events 3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Nail infection
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 5 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Nervous system disorders
Neurology (Other) - Drowsiness
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Neutrophil count decreased
|
33.3%
1/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Night Sweats
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Blurred Vision
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Dysfunctional Tear Syndrome
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Edema Lids
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Increased Eye Pressure
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Irritated Eyes
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Ocular Conjunctive Hemmorhage
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Ocular/Visual (Other) - Watery eyes
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Oral pain
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Otitis media
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Pain (Other)
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Musculoskeletal and connective tissue disorders
Pain (Other) - L Thigh
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
83.3%
5/6 • Number of events 9 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary (Other) - Chest Congestion
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
66.7%
2/3 • Number of events 5 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Rash desquamating
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis infective
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Serum magnesium decreased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Investigations
Serum phosphate decreased
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Sinusitis
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Injury / Laceration
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Sweating
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Treatment related secondary malignancy (Specify, Other) - SCC
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory infection
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Vascular disorders
Vascular (Other)
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
0.00%
0/6 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Vision blurred
|
33.3%
1/3 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Gastrointestinal disorders
Vomiting
|
33.3%
1/3 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 4 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
General disorders
Watering eyes
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
33.3%
2/6 • Number of events 2 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Skin and subcutaneous tissue disorders
Wound infection - Injury / Laceration
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
|
Infections and infestations
Wound infection - Injury / Laceration / Infection
|
0.00%
0/3 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
16.7%
1/6 • Number of events 1 • All Adverse Events were collected through Study Completion (Avg. 1 Year)
Toxicity graded using NCI Common Terminology Criteria for Adverse Events, v3.0 Nonheme Pomalidomide dose limiting toxicity gr 3 \~\>except gr3\> fatigue, nausea/vomiting, or nonheme abnormal labs resolving to gr1 / baseline 14 days 1st dose. Hematologic toxicity defined as gr4 neutropenia lasting \> 14 days, febrile neutropenia, thrombocytopenia (plt #\< 25k) \> 14 days. All AEs recorded from study entry/first dose-30 days after last dose and/or AE resolution:1/1/2011 to 6/7/2022.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place